RecruitMe Clinical Trial
ADVL1414, A Phase 1 Study of Selinexor (KPT-330), a Selective XP01 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Study of Selinexor in Pediatric Solid Tumors, including CNS Tumors
| Sponsor: | Children's Oncology Group |
| Enrolling: | Male and Female Patients |
| Age Range: | Between 1 and 21 years old |
| IRB Number: | AAAQ4204 |
| U.S. Government ID: | NCT02323880 |
| Contact: | Alice Lee, MD: 212-305-7212 / al2041@cumc.columbia.edu |
Additional Study Information:
We are testing new experimental drugs such as selinexor in the hopes of finding a treatment that may be effective against tumors that have come back or that have not responded to standard therapy. The goals of this study are: To find the highest safe dose of selinexor that can be given without causing severe side effects; To learn what kind of side effects selinexor can cause; To learn more about the pharmacology (how your body handles the drug) of selinexor; To learn more about the biology of selinexor in blood and tumor tissue; To determine whether selinexor is a beneficial treatment for your tumor.
